Alcon: Hypertension trials

The registry lists 104 Hypertension studies with Alcon as lead sponsor. 0 are open to participants now and 45 have results posted.

Phase 1 2Phase 2 28Phase 3 47Phase 4 26No phase 3(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular HypertensionCompletedNCT04620135Phase 3Results posted
• Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in JapanCompletedNCT03844945Phase 2Results posted
• Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world SettingCompletedNCT03808688Phase 4Results posted
• Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular HypertensionCompletedNCT03310580Phase 2Results posted
• Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular HypertensionCompletedNCT03284853Phase 3Results posted
• Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)CompletedNCT03233308Phase 2Results posted
• A Three Part Study of MGV354 in Ocular Hypertension or GlaucomaCompletedNCT02743780Phase 1/2Results posted
• Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular HypertensionCompletedNCT02674854Phase 3Results posted
• Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionCompletedNCT02558400Phase 3Results posted
• Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular HypertensionCompletedNCT02558374Phase 3Results posted
• Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)CompletedNCT02339584Phase 3Results posted
• Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionCompletedNCT02246764Phase 3Results posted
• Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular HypertensionCompletedNCT02207621Phase 3Results posted
• Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionCompletedNCT02207491Phase 3Results posted
• 6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT02140060Phase 2Results posted
• Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular PressureCompletedNCT02057575Phase 2Results posted
• Efficacy of Travoprost/Timolol for Uncontrolled Intraocular PressureCompletedNCT02003391Phase 4Results posted
• Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension GlaucomaCompletedNCT01995136Phase 4Results posted
• Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT01978600Phase 4Results posted
• An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®CompletedNCT01664039Phase 4Results posted
• Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma PatientsCompletedNCT01658839Phase 1Results posted
• Study of AR-13324 in Patients With Elevated Intraocular PressureCompletedNCT01528787Phase 2Results posted
• Efficacy of Changing to TRAVATAN® From Prior TherapyCompletedNCT01510145Phase 4Results posted
• Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)CompletedNCT01464424Phase 4Results posted
• Travoprost 3-Month Safety and Efficacy StudyCompletedNCT01453855Phase 3Results posted
• A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%CompletedNCT01426867Phase 2Results posted
• Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in CanadaCompletedNCT01415401Phase 4Results posted
• Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular HypertensionCompletedNCT01357616Phase 3Results posted
• Patient Preference Comparison of AZARGA Versus COSOPTCompletedNCT01340014Phase 4Results posted
• Efficacy of Changing to DUOTRAV® From Prior TherapyCompletedNCT01327599Phase 4Results posted
• Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular HypertensionCompletedNCT01310777Phase 3Results posted
• Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular HypertensionCompletedNCT01309204Phase 3Results posted
• Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%CompletedNCT01297920Phase 3Results posted
• Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%CompletedNCT01297517Phase 3Results posted
• Safety and Efficacy of Brinzolamide/Brimonidine Fixed CombinationTerminatedNCT00961649Phase 2Results posted
• Efficacy Study of Travoprost APS Versus TRAVATANCompletedNCT00848536Phase 3Results posted
• Examination of Ocular Surface Effects With Administration of Travatan Z and XALATANCompletedNCT00798759Phase 4Results posted
• Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular HypertensionCompletedNCT00763061Phase 4Results posted
• Phase III Clinical Trial of TRAVATAN Z in Ocular Surface HealthCompletedNCT00761319Phase 3Results posted
• Effects of Travatan Z and Xalatan on Ocular Surface HealthCompletedNCT00708422Phase 4Results posted
• Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00690794Phase 3Results posted
• A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00527592Phase 4Results posted
• Adherence Assessment With Travalert Dosing AidCompletedNCT00508469Phase 4Results posted
• A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular HypertensionCompletedNCT00471380Phase 4Results posted
• Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular HypertensionTerminatedNCT00471068Phase 4Results posted
• A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 DaysCompletedNCT01789736Phase 2
• Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in RussiaWithdrawnNCT01696383Phase 4
• Travacom Post Marketing Surveillance StudyWithdrawnNCT01510132Phase 4
• AR-12286 Fixed Dose Combination to Lower Elevated Intraocular PressureCompletedNCT01474135Phase 2
• Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%WithdrawnNCT01452009Phase 3
• 24-hour Efficacy of AR-12286CompletedNCT01330979Phase 2
• Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412CTerminatedNCT01312454Phase 2
• AR-12286 in Combination With LatanoprostCompletedNCT01302249Phase 2
• Divided Dose of TRAVATAN®CompletedNCT01298687Phase 2
• Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular HypertensionCompletedNCT01111890Phase 4
• Safety Study of DuoTrav APS in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00928590Phase 3
• Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface HealthCompletedNCT00892762Phase 3
• Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00872651Phase 3
• Safety and Efficacy Study of DuoTrav APS Versus DuoTravWithdrawnNCT00862472Phase 3
• A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular HypertensionTerminatedNCT00788541Phase 2
• Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPTTerminatedNCT00767494Phase 3
• 1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPTTerminatedNCT00767481Phase 3
• Safety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Reducing Intraocular Pressure in Patients With Open Angle Glaucoma or Ocular HypertensionCompletedNCT00761995Phase 4
• Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00761709Phase 2
• Safety and Efficacy of Travoprost/Timolol BAC-freeCompletedNCT00760539Phase 3
• Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular HypertensionCompletedNCT00759239Phase 4
• Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00691717Phase 2/3
• Glaucoma Adherence Study, SpainCompletedNCT00680329
• Glaucoma Adherence StudyCompletedNCT00676637
• A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00672997Phase 3
• Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose TravoprostCompletedNCT00637130Phase 2
• Adjunctive Study of AL-37807 Ophthalmic SuspensionCompletedNCT00620256Phase 2
• Patient Preference StudyCompletedNCT00576342Phase 3
• IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00527501Phase 2
• A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular HypertensionCompletedNCT00465803Phase 3
• Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00465621Phase 2
• A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00372931Phase 2
• Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular HypertensionCompletedNCT00372827Phase 4
• A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00333125Phase 3
• A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00326092Phase 2
• A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00314171Phase 3
• A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00314158Phase 3
• A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00311389Phase 3
• Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular HypertensionCompletedNCT00300079Phase 4
• A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00293800Phase 3
• A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00293787Phase 3
• A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00293761Phase 3
• Phase III Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension PatientsCompletedNCT00288951Phase 3
• A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00287521Phase 2
• Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension PatientsCompletedNCT00069719Phase 2
• Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension PatientsCompletedNCT00069706Phase 2
• Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular HypertensionCompletedNCT00061542Phase 3
• A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00061529Phase 3
• Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular HypertensionCompletedNCT00061516Phase 3
• Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular HypertensionCompletedNCT00061503Phase 4
• A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular HypertensionCompletedNCT00051194Phase 2
• A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)CompletedNCT00051155Phase 3
• A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)CompletedNCT00051142Phase 3
• Phase 4 Study Comparing IOP Lowering in OAG or OH in Caucasian or Japanese Subjects C-02-32TerminatedNCT00047606Phase 4
• Phase 3 Study Comparing IOP Lowering in OAG or OH in Japanese Subjects C-01-98CompletedNCT00047593Phase 3